www.fdanews.com/articles/96544-lev-pharmaceuticals-submits-biologics-license-application-for-cinryze
Lev Pharmaceuticals Submits Biologics License Application for Cinryze
July 31, 2007
Lev Pharmaceuticals, Inc. announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of its C1 inhibitor, proposed to be marketed as Cinryze, for the acute treatment of hereditary angioedema (HAE).
CNN Money